To compare the efficacy and safety of 532 nm KTP and 585 nm PDL for treating rosacea.
Rosacea is a common, chronic inflammatory skin disease that usually affects the cheeks, nose, forehead, and chin \[1\]. Clinically, it presents initially with transient erythema (flushing) and telangiectasia. As it progresses, persistent erythema and papules and pustules appear. Phymatous changes result from hypertrophy of the sebaceous glands, and usually manifest as rhinophyma, gnatophyma, and metophyma \[2\]. Depending on the literature, rosacea has a prevalence of 1% to 22% \[3\]. Time of manifestation of the disease is usually between 30 and 50 years \[4\]. Women are more frequently affected \[4\]. For laser treatment of rosacea, the pulsed dye laser (PDL) with a wavelength of 595nm is frequently used. The treatment includes at least three sessions at intervals of about 4 weeks and leads to lightening and reduction of the lesions as well as reduction of papules and pustules. Various clinical studies have already demonstrated the high efficacy of PDL \[5-7\]. The treatment is painless, and local or general anesthesia is not necessary. The KTP laser is also an option in the treatment of rosacea. Due to the more stable technology of the frequency-doubled Nd:YAG (KTP) and associated lower maintenance problems, this laser system appears to be a safer and more reliable treatment option for rosacea patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Laser Department, University Medical-Center Hamburg-Eppendorf
Hamburg, Germany
RECRUITINGreduction of erythema
assessment scale 0 - 4 (normal skin - severe erythema) evaluated by physician and blinded investigator
Time frame: at follow-up visit 4 weeks after last treatment session
pain intensity
using numeric rating scale 0 - 10 (none - unbearable pain) evaluated by subjects
Time frame: at follow-up visit 4 weeks after last treatment session
swelling
assessment scale 1 - 6 (very - none) evaluated by subjects
Time frame: at follow-up visit 4 weeks after last treatment session
purpura
assessment scale 1 - 6 (very - none) evaluated by subjects
Time frame: at follow-up visit 4 weeks after last treatment session
patient satisfaction
assessment scale 1 - 6 (very - not at all) evaluated by subjects
Time frame: at follow-up visit 4 weeks after last treatment session
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.